Help us: Donate
Follow us on:
×

Menu

Back

Tag: CRISPR

George Church Interview
Professor of Genetics at Harvard Medical School and one of the most prominent geroscientists, George Church works on gene therapies that can potentially reverse age-related diseases. We had the opportunity to interview this prolific researcher and entrepreneur, who is involved in dozens of startups on topics ranging from the current state of gene therapy to...
Neuropathy
Intellia has released clinical data for NTLA-2001, a gene therapy for hereditary transthyretin amyloidosis. What is transthyretin amyloidosis? Transthyretin (ATTR) amyloidosis is the buildup of misfolded transthyretin, a protein generated by the liver. Normally, this protein is partially responsible for the transport of thyroid hormones, hence its name; however, transthyretin is vulnerable to mutations and...
Journal Club
The Journal Club hosted by Dr. Oliver Medvedik will return live to our Facebook Page at 12:00 EST on Tuesday 27th of April. This month we will be taking a look at a new paper and technique for the gene editing tool CRISPRcas9. The technique allows researchers to turn epigenetic methylation off and back on...
Epigenetic wrapping
A new technique allows researchers to turn epigenetic methylation off and back on again, thus allowing the silencing and unsilencing of certain genes. A CRISPR breakthrough CRISPR/Cas9 is a well-known technology for editing the genome, but its potential for epigenetic editing had never been previously explored. With a directed CRISPR memory writer able to methylate...
Nanoparticles in blood
Scientists have successfully tested a new nanoparticle-based delivery system for CRISPR kits, achieving drastic improvements in mouse models of glioblastoma and ovarian cancer [1]. A gift from our single-cell ancestors CRISPR gene editing technology has been widely hailed as a potential game changer in medicine, including anti-cancer therapy. CRISPR’s ability to permanently disrupt tumor survival...
Gene segment
Researchers have successfully used the CRISPR/Cas9 gene editing tool to destroy Ewing's sarcoma and chronic myeloid leukemia tumor cells by targeting the fusion genes responsible for these tumors [1]. Fusion genes, a feature in many different types of cancer, arise when a mutation fuses two genes together, which typically happens when the DNA sequence between...